Product Information
PANTOPRAZOLE DR 40 MG SUSP PKT is a generic product labeled by Cipla USA Inc., priced at $3.8490 per EA under NDC 69097053153. Its NADAC has been published 61 times since Aug 6, 2025.
FDA first approved this application on Mar 31, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
40 mg/1
Manufacturer
Cipla USA Inc.NDC
69097053153
Classification
Generic
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PANTOPRAZOLE SODIUMApproval Type
Generic (ANDA)
FDA Application
ANDA217458FDA Approved
3/31/2025
TE Code
AB
On Market Since
4/3/2025
Pharmacological Classes
Price Statistics
The NADAC for PANTOPRAZOLE DR 40 MG SUSP PKT has been published 61 times since Aug 6, 2025, and over the history we have for it it has declined 40.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.8490 per EA |
|---|---|
| All-time high | $6.4752 (Aug 13, 2025) |
| All-time low | $3.8490 (Sep 23, 2026) |
| 52-week high | $5.6075 |
| 52-week low | $3.8490 |
| Median price | $4.3944 |
| Average price | $4.6215 |
| Largest weekly change | -15.4% (Oct 22, 2025) |
| Weeks tracked | 61 |
| Tracking since | Aug 6, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the pantoprazole sodium granules market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cipla USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
pantoprazole sodium granules market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Proton Pump Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PANTOPRAZOLE DR 40 MG SUSP PKT?
The current National Average Drug Acquisition Cost (NADAC) for PANTOPRAZOLE DR 40 MG SUSP PKT, manufactured by Cipla USA Inc., is $3.8490 per EA (NDC 69097053153), effective Sep 30, 2026.
How has the price of PANTOPRAZOLE DR 40 MG SUSP PKT changed over time?
Over the history we have for it, the NADAC for PANTOPRAZOLE DR 40 MG SUSP PKT has declined 40.6%. It has been tracked across 61 weekly CMS publications since Aug 6, 2025.
What are the highest and lowest recorded NADAC prices for PANTOPRAZOLE DR 40 MG SUSP PKT?
Since Aug 6, 2025, the NADAC for PANTOPRAZOLE DR 40 MG SUSP PKT has ranged from a low of $3.8490 (Sep 23, 2026) to a high of $6.4752 (Aug 13, 2025), with a median of $4.3944 per EA.
Are there cheaper alternatives to PANTOPRAZOLE DR 40 MG SUSP PKT?
No other NADAC-published product currently shares the active ingredient and strength of PANTOPRAZOLE DR 40 MG SUSP PKT in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PANTOPRAZOLE DR 40 MG SUSP PKT?
PANTOPRAZOLE DR 40 MG SUSP PKT (NDC 69097053153) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.